Circio Holding ASA (TRVXO)

Overview

Circio Holding ASA operates within the dynamic field of cancer immunotherapy and RNA therapeutics, focusing on the development of innovative treatments for cancer patients. The company was originally established in 2010 under the name Targovax ASA, before rebranding to Circio Holding ASA in May 2023. Located in Lysaker, Norway, Circio Holding has marked its presence in the biotechnology industry by advancing a promising portfolio of product candidates designed to harness the power of the immune system to fight cancer. Besides its clinical developments, the company engages in strategic collaborations, including with the University of Kansas Cancer Center and Neoregen Biotech, to enhance its research capabilities and expand its therapeutic pipeline.

Products and Services

• ONCOS-102

  This lead product candidate exemplifies Circio Holding ASA's commitment to advancing cancer care through immunotherapy. ONCOS-102 is an innovative treatment designed for patients suffering from mesothelioma and melanoma cancers. By targeting these aggressive forms of cancer, ONCOS-102 aims to stimulate the immune system to recognize and fight the cancer cells more effectively, offering hope for improved outcomes in these difficult-to-treat conditions.

• TG-01

  Expanding its portfolio into cancer vaccines, Circio Holding ASA is developing TG-01, a program that leverages the concept of neoantigen vaccines to target mutant KRAS cancers. KRAS mutations are prevalent in various cancer types and are known for their resistance to conventional therapies. TG-01 represents a groundbreaking approach by potentially enabling the immune system to target and destroy cancer cells harboring these mutations, thereby addressing a critical unmet need in oncology.

• ONCOS Immunotherapy Technologies

  The ONCOS platform underscores the company's focus on novel therapeutic strategies to enhance the immune response against cancer. This technology suite includes a range of approaches designed to modulate the immune system's ability to identify and eliminate tumor cells. By continually developing these technologies, Circio Holding ASA aims to offer new therapeutic options that can be tailored to meet the specific needs of diverse patient populations.

• Collaborative Research Projects

  In pursuit of innovative therapies, Circio Holding ASA collaborates with esteemed institutions and biotech firms, such as the University of Kansas Cancer Center and Neoregen Biotech. These partnerships focus on the development of novel therapeutic candidates and delivery mechanisms, including NICT-delivered circVec therapeutic candidates. These collaborative efforts not only broaden the company's research capabilities but also accelerate the pace of discovery and development of next-generation cancer treatments.